Kinase inhibitors such as Staurosporine and U0126, can impede phosphorylation events that are essential for the regulation of protein function and signaling pathways. If C17orf48 is regulated by phosphorylation, these inhibitors can effectively reduce its activity. The cellular energy state and metabolic pathways are also potential areas of influence. Chemicals such as LY294002 and Wortmannin target the PI3K/AKT pathway, a critical axis in the regulation of cell survival, metabolism, and growth. Disruption of this pathway can lead to changes in the cellular functions that C17orf48 may be involved in. Similarly, the use of 2-Deoxy-D-glucose can compromise the glycolytic pathway, potentially affecting proteins associated with cellular metabolism.
The process of autophagy, which is crucial for cellular homeostasis and protein turnover, is another target. Compounds like Rapamycin and Bafilomycin A1 modulate autophagy and lysosomal function, respectively. Such modulation can have wide-reaching implications for cellular protein pools, including C17orf48, especially if it is a protein subjected to turnover via these pathways. Additionally, inhibitors of molecular chaperones, such as 17-AAG, which targets Hsp90, can destabilize client proteins and affect protein folding processes that could be vital for the proper function of C17orf48.
SEE ALSO...
Items 11 to 12 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
An inhibitor of the V-ATPase proton pump that can disrupt lysosomal acidification and autophagy, potentially affecting C17orf48 activity. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
A glycolysis inhibitor that can alter energy metabolism, potentially impacting C17orf48 if it is linked to metabolic pathways. |